Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.
News|Articles|March 4, 2026
Top ASCO GU 2026 Takeaways for Nurses and APPs
Author(s)Oncology Nursing News Staff
Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.
Advertisement
Advertisement
The 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium featured several high-impact studies detailing therapeutic advancements and patient-reported outcomes (PROs) across bladder, renal, and prostate cancers. For oncology nurses and advanced practice providers (APPs), these findings provide essential data on new treatment combinations, evolving safety profiles, and the long-term impact of therapy on patient quality of life (QOL).
Related to this article
Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
Advertisement
Advertisement